Europe's rich heritage in pharmaceutical innovation has significantly shaped the global landscape. Yet, recent decades have seen this continent cede its leading position to the U.S. and witness emerging markets like China and India surge ahead. The question now is whether Europe can chart a path
BioAge Labs has recently garnered significant attention with its successful initial public offering (IPO), raising a formidable $198 million. Demonstrating the company's strategic pivot towards obesity drug research, this financial feat is particularly notable given the challenging environment for
In a significant move within the life sciences industry, Cryoport, Inc. and SK pharmteco have announced a strategic partnership focused on advancing cell and gene therapy. This collaboration aims to integrate logistics and manufacturing services for biotechnology and pharmaceutical companies,
Mpox has made a concerning comeback, compelling immediate and collaborative action. With an increased threat from the Clade Ib strain, the situation demands an effective response framework modeled after successful strategies used in the COVID-19 pandemic. This involves substantial input from both
KBI Biopharma, a prominent contract development and manufacturing organization (CDMO), encountered a critical issue during a GMP (Good Manufacturing Practice) production run. An unexpected pink discoloration appeared in the cell culture media, a crucial component for biologic drug production. The
The clinical research landscape is on the cusp of a transformative shift with the U.S. Food and Drug Administration (FDA) poised to implement a groundbreaking regulation by May 2025. This regulation mandates the use of a single, centralized institutional review board (sIRB) for multisite trials,
The resignation of Mr. Zhou Honghao, an independent non-executive director from Genor Biopharma Holdings Limited, has sparked considerable debate and concern among investors and market watchers. With the effective date of the resignation set for September 18, 2024, there are critical questions to
The biotech sector is brimming with opportunities that extend far beyond the much-talked-about GLP-1 weight-loss drugs, which have garnered significant attention following the 2024 European Association for the Study of Diabetes (EASD) meeting. While GLP-1 treatments, led by giants like Eli Lilly
GC Therapeutics (GCTx), a biotech company founded in 2019, has captured the spotlight with its pioneering approach to cell therapy. With a mission centered on advanced induced pluripotent stem cell (iPSC)-based medicines, GCTx is driven by its innovative TFome platform. Bolstered by a successful
The competitive landscape of pharmaceutical treatments for achondroplasia, a common cause of dwarfism, is experiencing a seismic shift, thanks to the recent clinical trial results from Ascendis Pharma. BioMarin Pharmaceutical, a long-time player in this niche market, finds itself under significant
